Clinical Trial Update: Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma [Phase 2]

View source ↗

Summary

A Phase II trial evaluating sorafenib with radiation and temozolomide for newly diagnosed glioblastoma or gliosarcoma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Nexavar (Sorafenib)
• Temodar (Temozolomide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Glioblastoma, Gliosarcoma | Phase 2 | Status: WITHDRAWN